Michigan lawmakers are moving closer to banning kratom, a botanical supplement derived from the leaves of the Southeast Asian Mitragyna speciosa tree, after a legislative hearing this month drew emotional testimony from grieving families alongside pushback from users who credit the substance with turning their lives around.
The bill, which has advanced through committee, would prohibit the sale, distribution, and possession of kratom products across the state. Supporters argue the measure is a necessary public health response. Opponents call it an overreach that would harm thousands of Michigan residents who use kratom to manage chronic pain, opioid withdrawal, anxiety, and other conditions.
The Case for the Ban
The most powerful testimony in favor of the legislation came from a mother who told lawmakers she lost her son to kratom. Her account placed a human face on what advocates for the ban describe as an underregulated and dangerous substance masquerading as a harmless herbal product.
The testimony followed a pattern familiar to Michigan legislators from prior debates over substances like synthetic cannabinoids and bath salts. A family suffers a loss. State data is incomplete. Regulators lack clear authority. Lawmakers respond with prohibition.
Those pushing the ban point to the U.S. Food and Drug Administration’s longstanding skepticism of kratom. The FDA has never approved kratom for any medical use and has issued multiple warnings about its potential for abuse, dependence, and serious adverse effects. The agency has linked kratom to deaths, though medical researchers note that most fatalities involving kratom also involved other substances, complicating the causal picture.
At the federal level, the Drug Enforcement Administration attempted to classify kratom as a Schedule I controlled substance in 2016 but reversed course after significant public opposition. That reversal did not settle the underlying science, and federal agencies have continued to flag concerns about the substance’s active compounds, mitragynine and 7-hydroxymitragynine, which interact with opioid receptors in the brain.
Kratom’s opioid receptor activity is central to the ban’s logic. Proponents argue that a substance acting on opioid pathways has no business sitting on the shelves of gas stations and supplement shops without prescription oversight. They also point to inconsistencies in product quality, with studies showing wide variation in the concentration of active compounds across commercially available kratom products.
The Case Against
Opponents of the ban who testified before Michigan legislators pushed back hard on the prohibition framing. Several users described kratom as the thing that allowed them to exit opioid addiction, manage conditions that did not respond to conventional treatment, or reduce their dependence on prescription medications with their own risk profiles.
This argument carries weight in a state that lived through the peak of the opioid crisis as acutely as anywhere in the country. Michigan recorded thousands of opioid overdose deaths across the past decade, and communities across the state remain skeptical of policies that restrict harm reduction tools without replacing them with something better.
Kratom advocates also cite a 2022 survey published in Drug and Alcohol Dependence, which found that a majority of kratom users reported using it to manage pain and that most described low rates of adverse effects. Critics of that research note that self-reported surveys of active users are not ideal instruments for measuring harm. Still, the data landscape is genuinely contested, and researchers at institutions including Johns Hopkins University have argued that kratom’s risk profile is significantly lower than that of classical opioids and that a scheduling ban would be counterproductive.
The American Kratom Association has been active in Michigan, as it has been in every state that has considered similar legislation. The organization frames bans as harmful to consumers and has pushed instead for a regulatory model it calls the Kratom Consumer Protection Act, which would require lab testing, age restrictions, accurate labeling, and prohibitions on adulterated products. Several states have adopted versions of this framework rather than outright prohibition.
How Michigan Compares
Michigan is not the first state to weigh a kratom ban, and its legislature is watching how other states have navigated the issue.
Six states currently ban kratom outright: Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin. Several others, including Arizona, Georgia, Nevada, and Utah, have taken the regulatory approach, passing consumer protection legislation that imposes quality standards and age restrictions without banning the substance entirely. That regulatory model is gaining traction as an alternative to the binary choice between prohibition and unregulated access.
Detroit sits on the front lines of this question in a way that Lansing sometimes does not fully account for. The city has a significant population of kratom users, with the substance available at smoke shops, supplement retailers, and convenience stores throughout the metro area. A state ban would abruptly eliminate that access, pushing demand toward unregulated online markets or across state lines where the product remains legal.
That displacement effect is one of the core arguments against prohibition models in public health. When regulated access disappears, demand rarely does. It migrates toward channels with less accountability, not more.
What the Bill Actually Does
The proposed legislation would classify kratom as a controlled substance, making its sale and possession illegal under state law. The bill does not appear to include provisions for a regulatory alternative or a transition period for existing businesses that sell kratom products.
That absence matters. Approximately 15 million Americans report using kratom, according to the American Kratom Association’s estimates. Michigan’s share of that population is substantial, and many of those users have built routines around the supplement over years. An abrupt ban with no regulatory alternative and no transition mechanism is a blunt instrument.
The primary sponsors are responding to constituent concerns and, in at least one visible case, to direct advocacy from families who experienced loss. That is a legitimate legislative input. But the accountability question does not stop there. Pharmaceutical industry influence on scheduling debates is well-documented at the federal level, and while there is no direct evidence of industry involvement in this particular Michigan bill, the pattern deserves scrutiny any time a ban would redirect chronic pain and addiction management patients toward prescription alternatives.
The Timeline
The bill has cleared committee and is positioned for a floor vote. Given the emotional weight of the testimony and the current makeup of the Michigan legislature, a vote before the end of the spring session is plausible. The governor’s office has not publicly committed to signing or vetoing the legislation if it passes.
If the bill becomes law, enforcement would fall to the Michigan State Police and local law enforcement agencies, who would need to treat kratom possession and sale as a criminal matter. That raises additional questions about resource allocation, prosecutorial discretion, and whether enforcement would land disproportionately on retailers in lower-income neighborhoods where kratom products are commonly sold.
What Residents Need to Know
For the roughly one to two million Michigan residents the American Kratom Association estimates use the supplement, the practical stakes are immediate. If the ban passes, kratom would become illegal to possess in the state. That affects not just recreational users, a framing that most users would reject given how they describe the substance as functional and therapeutic, but also people who have integrated kratom into their management of chronic pain and opioid use disorder.
There is no clinical treatment protocol for kratom dependence currently recognized in Michigan, and there are no FDA-approved medications specifically targeting kratom withdrawal. People who experience dependence and need to stop suddenly would largely be on their own.
The public health data on kratom does not support a clear verdict in either direction, which makes honest policymaking difficult. What the data does support is that regulation produces better outcomes than prohibition for substances with established consumer bases, contested risk profiles, and no simple pharmaceutical substitute.
Michigan has a chance to follow the lead of states that passed consumer protection frameworks rather than bans. Whether lawmakers take that path before a floor vote is the question that will define the outcome for residents across the state.
The committee vote happened. The floor vote is next. The window for a course correction toward a regulatory model is open, but it will not stay open indefinitely.
